Fmr LLC Design Therapeutics, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 81,016 shares of DSGN stock, worth $474,753. This represents 0.0% of its overall portfolio holdings.

Number of Shares

81,016

Previous 78,341 3.41%

Holding current value

$474,753

Previous $315,000 13.97%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$3.23 - $4.77 $8,640 - $12,759	2,675 Added 3.41%	81,016 $271,000
Q1 2024 May 13, 2024	SELL	$2.27 - $4.03 $1,523 - $2,704	-671 Reduced 0.85%	78,341 $315,000
Q4 2023 Feb 13, 2024	BUY	$1.99 - $2.76 $17,818 - $24,713	8,954 Added 12.78%	79,012 $209,000
Q3 2023 Nov 13, 2023	SELL	$2.05 - $8.14 $1.16 Million - $4.62 Million	-567,712 Reduced 89.02%	70,058 $165,000
Q2 2023 Aug 11, 2023	SELL	$4.99 - $7.64 $1.6 Million - $2.45 Million	-320,133 Reduced 33.42%	637,770 $4.02 Million
Q1 2023 May 11, 2023	SELL	$5.5 - $9.77 $888,987 - $1.58 Million	-161,634 Reduced 14.44%	957,903 $5.53 Million
Q4 2022 Feb 13, 2023	BUY	$7.86 - $17.2 $288,265 - $630,810	36,675 Added 3.39%	1,119,537 $11.5 Million
Q3 2022 Nov 10, 2022	BUY	$14.09 - $25.57 $787,940 - $1.43 Million	55,922 Added 5.45%	1,082,862 $18.1 Million
Q2 2022 Aug 12, 2022	SELL	$9.91 - $17.33 $4,221 - $7,382	-426 Reduced 0.04%	1,026,940 $14.4 Million
Q1 2022 May 13, 2022	BUY	$11.17 - $20.89 $305,678 - $571,675	27,366 Added 2.74%	1,027,366 $16.6 Million
Q2 2021 Aug 13, 2021	BUY	$19.02 - $29.78 $19 Million - $29.8 Million	1,000,000 New	1,000,000 $19.9 Million

Others Institutions Holding DSGN

# of Institutions

Shares Held

31.9M

Call Options Held

1.1K

Put Options Held

21.3K

View Full List

About Design Therapeutics, Inc.

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $327M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

More about DSGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account